• 제목/요약/키워드: CJ-50002

검색결과 3건 처리시간 0.015초

Vibrio vulnificus에 대한 경구용백신 CJ-50002의 일반약리작용 (General Pharmacology of CJ-50002, an Oral Vaccine against Vibrio vulnificus Infection)

  • 김영훈;정성목;신재규;최재묵;이나경;박완제;이윤하;이영수
    • Biomolecules & Therapeutics
    • /
    • 제7권1호
    • /
    • pp.89-96
    • /
    • 1999
  • CJ-50002 is an oral vaccine against V.vulnificus infection composed of whole cell lysate of V. vulnificus. The general pharmacological properties of CJ-50002 were evaluated in various animals and in vitro system. CJ-50002 at oral doses of 0.2, 2 and 20 mg/kg had no effect on general behavior in mice, chromo- and electro-convulsions in mice, writhing syndrome induced by acetic acid in mice, body temperature in rats, charcoal meal propulsion in mice and urine and electrolytes excretion in rats. However, oral administration of CJ-50002 at dose of 20 mg/kg prolonged the hexobarbital-inuced sleeping inducing time in mice. In anesthetized dogs, CJ-50002 showed no effect on blood pressure, heart rate and ECG but decreased the respiratory rate and femoral blood flow at dose of 20 mg/kg. p.o. CJ-50002 had no effect on the contractile response of the isolated guinea pig ileum to various spasmogen at concentrations of 0.2, 2 and 20 $\mu\textrm{g}$/ml, respectively. Since these pharmacological effects of CJ-500o2 were observed at dose much greater than those in clinical use (approximately 0.16 mg/kg, p.o.), it is likely that this vaccine may be relatively free of undesirable effects in clinical practice.

  • PDF

비글개에서 CJ-50002(비브리오백신)의 4주간 경구 반복투여 독성시험 (Four-Week Oral Toxicity Studies of CJ-50002 (Vibrio Vaccine) in Beagle Dogs)

  • 이광훈;제정환;강병철;이원우;임종희;정지윤;김달현;이영수;이영순
    • Toxicological Research
    • /
    • 제15권1호
    • /
    • pp.55-63
    • /
    • 1999
  • This study was carried out to investigate the four-week oral toxicity of the CH-50002 (Vibril vaccine) in beagle dogs. The beagle dogs were orally administered for 28 days, with dosage of 0.5, 5, 50 mg/kg/day, respectively. Animals treated with CJ-50002(Vibrio Vaccine) did not cause any death and show any clinical signs. There were not significantly different from the control group in urinalysis, ocular examination, hematological, serum biochemical value and histopathological examination. Therefore, CJ-50002(Vibrio Vaccine) was not indicated to have any toxic efent in the beagle dogs, when ti was orally administered below the dosage 50mg/kg/day for rour weeks.

  • PDF

CJ-50002(비브리오백신)의 랫드에 대한 4주간 경구 반복투여 독성연구 (Four-Week Oral Toxicity Study of CJ-50002 (Vibrio Vaccine) in Rats)

  • 윤병일;정수연;김달현;이영수;김대용
    • Toxicological Research
    • /
    • 제15권1호
    • /
    • pp.9-17
    • /
    • 1999
  • This study was performed to evaluate the subacute toxicity of CJ-50002 (Vibrio Vaccine) in SPF Spraqur-Dawley (SD) rats. Vibrio vaccine was administered orally at a dose level of high (167mg/kg/day), medium (16.7mg/kg/day), and low (16.7mg/kg/day) once a day and repeated fro 4 weeks. Ten males and female rats were assigned to each group. After 4 week administration, no significant dose-dependent changes in body weight, water and food consumption rate or organ weight were noted dependent changes in body weight, water and food consumption rate or organ weight were noted among 4 groups. Urinanalysis, hematology, and serum chemistry, also fail to detect any dose-related change among 4 groups tested. During necropsy and histopathological examination, no specific toxicity related to treated material was found. The result of this study demonstrated that vibrio vaccine when administered orally for 4 weeks at a high dose of 167mg/kg/day, no dose-related toxicity was found in treated make and female rats.

  • PDF